CN111773172A - Anti-aging skin care product containing human autologous plasma cytokine group growth factors and preparation method thereof - Google Patents
Anti-aging skin care product containing human autologous plasma cytokine group growth factors and preparation method thereof Download PDFInfo
- Publication number
- CN111773172A CN111773172A CN202010876014.5A CN202010876014A CN111773172A CN 111773172 A CN111773172 A CN 111773172A CN 202010876014 A CN202010876014 A CN 202010876014A CN 111773172 A CN111773172 A CN 111773172A
- Authority
- CN
- China
- Prior art keywords
- care product
- growth factor
- skin care
- plasma
- human autologous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003102 growth factor Substances 0.000 title claims abstract description 51
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 41
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 41
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 22
- 238000000746 purification Methods 0.000 claims abstract description 12
- 230000010261 cell growth Effects 0.000 claims abstract description 10
- 238000005119 centrifugation Methods 0.000 claims abstract description 8
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 229940088597 hormone Drugs 0.000 claims abstract description 7
- 239000005556 hormone Substances 0.000 claims abstract description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 7
- 239000011707 mineral Substances 0.000 claims abstract description 7
- 235000010755 mineral Nutrition 0.000 claims abstract description 7
- 239000011573 trace mineral Substances 0.000 claims abstract description 7
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 7
- 229940088594 vitamin Drugs 0.000 claims abstract description 7
- 239000011782 vitamin Substances 0.000 claims abstract description 7
- 235000013343 vitamin Nutrition 0.000 claims abstract description 7
- 229930003231 vitamin Natural products 0.000 claims abstract description 7
- 210000000601 blood cell Anatomy 0.000 claims abstract description 6
- 230000004936 stimulating effect Effects 0.000 claims abstract description 6
- 210000004369 blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 230000008014 freezing Effects 0.000 claims description 14
- 238000007710 freezing Methods 0.000 claims description 14
- 210000003743 erythrocyte Anatomy 0.000 claims description 10
- 239000003146 anticoagulant agent Substances 0.000 claims description 7
- 229940127219 anticoagulant drug Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000010257 thawing Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 210000002421 cell wall Anatomy 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 5
- 238000000703 high-speed centrifugation Methods 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 58
- 230000037303 wrinkles Effects 0.000 abstract description 10
- 230000008439 repair process Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 238000011069 regeneration method Methods 0.000 abstract description 7
- 230000002087 whitening effect Effects 0.000 abstract description 7
- 231100000241 scar Toxicity 0.000 abstract description 5
- 210000004180 plasmocyte Anatomy 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 4
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 230000003661 hair follicle regeneration Effects 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 230000004520 agglutination Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 10
- 230000001815 facial effect Effects 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 238000003860 storage Methods 0.000 description 6
- 208000032544 Cicatrix Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000037314 wound repair Effects 0.000 description 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 201000010251 cutis laxa Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010033474 Pain of skin Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940072041 transforming growth factor beta 2 Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/983—Blood, e.g. plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of cosmetic preparation, and particularly relates to an anti-aging skin care product of a human autologous plasma cell active factor group growth factor and a preparation method thereof. An anti-aging skin care product of human autologous plasma cytokine group growth factors comprises the following components: 100% of the extract is from autologous blood cell group, and the plasma mixed extract containing complete active cytokines, trace elements, minerals, vitamins and hormones and a plurality of active elements for stimulating cell growth is obtained by extraction, purification, concentration and purification. The autologous plasma cell active factor group growth factor contained in the skin care product is obtained by centrifugation, agglutination, wall breaking, concentration and extraction of autologous active cells, and the activity of various complete cell factors contained in the skin care product is fully ensured; the effects of self-regeneration and repair, anti-aging and skin-tendering, wound healing and hair follicle regeneration are exerted through direct smearing or micro-needle injection, so that the effects of wrinkle removal, scar repair, skin whitening and skin tightening are achieved.
Description
Technical Field
The invention belongs to the technical field of cosmetic preparation, and particularly relates to an anti-aging skin care product of a human autologous plasma cell active factor group growth factor.
Background
Skin aging refers to the aging damage of skin function, which reduces the protection ability and regulation ability of skin to human body, so that the skin can not adapt to the change of internal and external environment, and the change of overall appearance conditions such as color, luster, shape, texture, etc. appears. Aging of the skin is classified into intrinsic aging and extrinsic aging. Endogenous aging refers to the natural aging of the skin as it ages. It is manifested as whitening of the skin, fine wrinkles, decreased elasticity, skin laxity, etc. The most prominent cause of extrinsic aging is photoaging due to sun exposure. Skin discoloration manifested as wrinkles, loose skin, roughness, yellowish or grayish yellow, telangiectasia, formation of pigmented spots, and the like.
The conventional cosmetics are almost prepared by mixing chemical organic solvents, can only solve the problems of water shortage and pigmentation on the surface of skin, and can treat the symptoms and the root causes. Once stopped, the skin is easy to relapse, but the long-term or frequent use of the medicine can cause great damage to skin tissues
In general skin care products, components which are easily sensitized such as perfumes, preservatives, and coloring matters are added. The addition of chemical sunscreen agents or powders, whitening components, acne-removing and bacteriostatic components, or macromolecular functional components obtained by pulling and tightening in special skin care products can result in more or less sensitive and even allergic skin.
Similarly, if the quality of basic ingredients such as oils and fats used in skin care products is poor, they are not easily absorbed by human skin, and acne, dermatitis, and the like are easily caused.
Some bioactive substances are gradually found to have whitening and anti-aging effects on human skin, for example, in human autologous cells, various active elements which stimulate cell growth, such as complete active cytokines, trace elements, minerals, vitamins, hormones, and the like are found.
Disclosure of Invention
In order to make various skin care product raw materials give full play to the functions and overcome the defect caused by singly using a certain component, the skin care product integrates the advantages of the raw materials, and makes the skin care product give full play to the functions of self-regeneration repair, anti-aging and skin tendering, wound healing and hair follicle regeneration so as to achieve the effects of removing wrinkles, repairing scars, whitening and firming the skin. The invention provides an anti-aging skin care product of a human autologous plasma cytokine population growth factor and a preparation method thereof.
The technical scheme provided by the invention is as follows:
an anti-aging skin care product of human autologous plasma cytokine group growth factors comprises the following components: 100% of the extract is from autologous blood cell group, and the plasma mixed extract containing multiple active elements for stimulating cell growth, such as complete active cytokines, trace elements, minerals, vitamins, hormones and the like, is obtained by extraction, purification, concentration and purification.
The invention also provides an anti-aging skin care product of the human autologous plasma cytokine group growth factor and a preparation method thereof, and the anti-aging skin care product comprises the following steps;
(1) collecting 100mL of human autologous venous blood in a vacuum blood collection tube or a blood collection bag containing an anticoagulant;
(2) transferring the blood collected in the step (1) into 15mL centrifugal tubes (each tube does not exceed 14.5mL), balancing, centrifuging for 300g and 15min respectively, extracting leucocyte layer cells and upper layer plasma, and centrifuging for 700g and 20 min;
(3) the resulting bottom erythrocyte pellet and growth factor protein were mixed with plasma in the same tube.
(4) And (4) repeatedly freezing and thawing the plasma centrifuge tube containing the growth factor protein obtained in the step (3) to break the cell wall and release the growth factors of the cytokine group.
(5) Performing high-speed centrifugation on the cells repeatedly frozen and thawed and crushed in the step (4) to remove a small amount of red blood cells, white blood cells and protein fragments to obtain the anti-aging skin care product of the human autologous plasma cytokine group growth factor;
(6) and (3) concentrating the plasma containing the human autologous plasma cytokine population growth factor obtained in the step (5) into 12-20mL, uniformly packaging into 4.5mL freezing tubes, and storing in an ultra-low temperature refrigerator at minus 80 ℃ for a long time.
Preferably, the collection condition of the 100mL human autologous venous blood in the step (1) is a vacuum blood collection tube or a blood collection bag containing an anticoagulant.
Preferably, in the step (2), the first-step centrifugation conditions are 300g, 15min centrifugation, 0 increasing speed and 0 decreasing speed; the second step of centrifugation is carried out under the conditions of 700g and 20 min.
Preferably, in the step (4), a repeated freezing and thawing method is adopted, so that the cell factors in the cells after wall breaking are all released under the condition of quick freezing for 30min at a temperature of between 50 ℃ below zero and 80 ℃ below zero, and then the cells are revived in water bath at a temperature of 37 ℃ for 10 min; repeating for 1-2 times.
Preferably, the high speed centrifugation conditions used in step (5) are 900g for 10 min.
Compared with the prior art, the invention has the beneficial effects that:
the human autologous plasma cytokine group growth factor contained in the skin care product is prepared by centrifuging, agglutinating, breaking the wall and concentrating autologous plasma, so that the activity of the human autologous plasma cytokine group growth factor is fully ensured; the skin anti-aging technology is a pure natural, additive-free, drug-free and operation-free skin anti-aging technology, and achieves the effects of removing wrinkles, whitening and removing acne marks by utilizing the functions of self-regeneration and repair, anti-aging and skin-tendering, wound healing and hair follicle regeneration.
Detailed Description
The present invention will be more readily understood by reference to the following examples, which are given without limiting the scope of the invention.
The human autologous plasma cytokine population growth factor mainly contains the following factors, and the content refers to the content of the factors contained in the skin care product.
Transforming growth factor-beta (TGF beta 1): aiming at the growth and differentiation of cells, the wound repair is promoted, the growth and angiogenesis of vascular endothelial cells are promoted, the regeneration of ossein is promoted, and the elasticity of skin is aimed. The content is 50-60 pg/mL.
② Vascular Endothelial Growth Factor (VEGF): promoting the growth and angiogenesis of vascular endothelial cells, promoting wound repair and aiming at the skin aging condition. The content is 10-15 pg/mL.
③ Hepatocyte Growth Factor (HGF): promoting cell growth and repair, and moisturizing skin. The content is 40-50 pg/mL.
(iv) Keratinocyte Growth Factor (KGF): accelerating wound healing, promoting skin repair and surface cell regeneration, and targeting skin tenderness and melanin. The content is 20-30 pg/mL.
Interleukin (IL): reduce inflammatory reaction. The content is 50-80 pg/mL.
Sixthly, fibroblast growth factor (bFGF): repairing damaged endothelial cells, promoting repair of various soft tissue injuries, can be used for wound, burn, ulcer, etc., secreting collagen, providing protection and support for skin, and aiming at wrinkles. The content is 30-60 pg/mL.
Seventhly insulin-like growth factor (IGF): promote cell differentiation, accelerate wound repair, and aim at skin compactness and brightness. The content is 10-20 pg/mL.
-Platelet Derived Growth Factor (PDGF): promoting cell growth and division, accelerating angiogenesis, and promoting ossein production. The content is 40-50 pg/mL.
Ninthly Epidermal Growth Factor (EGF): promoting skin growth and repair, and promoting ossein regeneration for pore and wrinkle. The content is 40-60 pg/mL.
C transforming growth factor- β 2/3(TGF β 2/3): promoting the regeneration of ossein and aiming at the elasticity of skin. The content is 30-50 pg/mL.
Example 1:
an anti-aging skin care product of human autologous plasma cytokine group growth factors comprises the following components: 100% of the extract is from autologous blood cell group, and the plasma mixed extract containing multiple active elements for stimulating cell growth, such as complete active cytokines, trace elements, minerals, vitamins, hormones and the like, is obtained by extraction, purification, concentration and purification.
The preparation method of the anti-aging skin care product of the human autologous plasma cytokine population growth factor comprises the following steps;
(1) collecting 100mL of human autologous venous blood in a vacuum blood collection tube or a blood collection bag containing an anticoagulant;
(2) transferring the blood collected in the step (1) into 15mL centrifugal tubes (each tube does not exceed 14.5mL), balancing, centrifuging for 300g and 15min respectively, extracting leucocyte layer cells and upper layer plasma, and centrifuging for 700g and 20 min;
(3) the resulting bottom erythrocyte pellet and growth factor protein were mixed with plasma in the same tube.
(4) Repeatedly freezing and thawing the plasma centrifuge tube containing the growth factor protein obtained in the step (3) to break the cell wall and release the cell active element group growth factor, quickly freezing for 30min at the temperature of-50 ℃, and then recovering for 10min in water bath at the temperature of 37 ℃; repeat 2 times.
(5) Centrifuging the cells repeatedly frozen and thawed and crushed in the step (4) at a high speed of 900g for 10min, and removing a small amount of red blood cells, white blood cells and protein fragments to obtain the anti-aging skin care product of the human autologous plasma cytokine group growth factor;
(6) concentrating the plasma containing a human autologous plasma cytokine population growth factor obtained in the step (5) into 12mL, subpackaging the 12mL plasma into 3 tubes per 4.0mL tube frozen storage tube on average, and storing in an ultra-low temperature refrigerator at-80 ℃ for long-term storage.
Example 2：
An anti-aging skin care product of human autologous plasma cytokine group growth factors comprises the following components: 100% of the extract is from autologous blood cell group, and the plasma mixed extract containing multiple active elements for stimulating cell growth, such as complete active cytokines, trace elements, minerals, vitamins, hormones and the like, is obtained by extraction, purification, concentration and purification.
The preparation method of the anti-aging skin care product of the human autologous plasma cytokine population growth factor comprises the following steps;
(1) collecting 100mL of human autologous venous blood in a vacuum blood collection tube or a blood collection bag containing an anticoagulant;
(2) transferring the blood collected in the step (1) into 15mL centrifugal tubes (each tube does not exceed 14.5mL), balancing, centrifuging for 300g and 15min respectively, extracting leucocyte layer cells and upper layer plasma, and centrifuging for 700g and 20 min;
(3) the resulting bottom erythrocyte pellet and growth factor protein were mixed with plasma in the same tube.
(4) Repeatedly freezing and thawing the plasma centrifuge tube containing the growth factor protein obtained in the step (3) to break the cell wall and release the cell active element group growth factor, quickly freezing for 30min at-80 ℃, and then recovering for 10min in water bath at 37 ℃; repeat 2 times.
(5) Centrifuging the cells repeatedly frozen and thawed and crushed in the step (4) at a high speed of 900g for 10min, and removing a small amount of red blood cells, white blood cells and protein fragments to obtain the anti-aging skin care product of the human autologous plasma cytokine group growth factor;
(6) concentrating the plasma containing a human autologous plasma cytokine population growth factor obtained in the step (5) into 12mL, subpackaging the 12mL plasma into 3 tubes per 4.0mL tube frozen storage tube on average, and storing in an ultra-low temperature refrigerator at-80 ℃ for long-term storage.
Example 3:
an anti-aging skin care product of human autologous plasma cytokine group growth factors comprises the following components: 100% of the extract is from autologous blood cell group, and the plasma mixed extract containing multiple active elements for stimulating cell growth, such as complete active cytokines, trace elements, minerals, vitamins, hormones and the like, is obtained by extraction, purification, concentration and purification.
The preparation method of the anti-aging skin care product of the human autologous plasma cytokine population growth factor comprises the following steps;
(1) collecting 100mL of human autologous venous blood in a vacuum blood collection tube or a blood collection bag containing an anticoagulant;
(2) transferring the blood collected in the step (1) into 15mL centrifugal tubes (each tube does not exceed 14.5mL), balancing, centrifuging for 300g and 15min respectively, extracting leucocyte layer cells and upper layer plasma, and centrifuging for 700g and 20 min;
(3) the resulting bottom erythrocyte pellet and growth factor protein were mixed with plasma in the same tube.
(4) Repeatedly freezing and thawing the plasma centrifuge tube containing the growth factor protein obtained in the step (3) to break the cell wall and release the cell active element group growth factor, quickly freezing for 30min at the temperature of-50 ℃, and then recovering for 10min in water bath at the temperature of 37 ℃; repeat 2 times.
(5) Centrifuging the cells repeatedly frozen and thawed and crushed in the step (4) at a high speed of 900g for 10min, and removing a small amount of red blood cells, white blood cells and protein fragments to obtain the anti-aging skin care product of the human autologous plasma cytokine group growth factor;
(6) concentrating the plasma containing a human autologous plasma cytokine population growth factor obtained in the step (5) into 20mL, subpackaging the 20mL plasma into 5 tubes per 4.0mL tube frozen storage tube on average, and storing in an ultra-low temperature refrigerator at-80 ℃ for long-term storage.
Investigation of use effect:
the using method comprises the following steps: one treatment course is 1 microneedle injection and smearing every 4 weeks, and 3 times continuous use, 3 times are concentrated dose for each production. Depending on the requirements of the user, repeated treatments may be continued. After 3 months, the face was observed and counted, and 100 cases were taken out each, and 3 groups of control cases, control case 1, control case 2 and control case 3 were set.
Table 1 investigation of the use effect of the skin care product of the present invention
Note: the control examples 1-3 contained autologous plasma alone and no human autologous plasma cytokine population growth factor, and the other conditions were the same as those in examples 1-3.
As can be seen from Table 1, in each of 100 trial cases, none of 1 of examples 1-3 had facial discomfort and other allergic phenomena; at least 2 cases of the skin is fine and smooth and has no obvious change; at least 80 cases of facial wrinkles are obviously eliminated; at least 50 cases of facial scars have detailed repair; at least 50 cases of pore reduction; at least 97 cases of facial skin are obviously fine and glossy.
Compared with the control example, the cases of obviously eliminating facial wrinkles, repairing facial scars with fine and fine, reducing pores and obviously fine and glossy facial skin are obviously higher than the control example. After the human autologous plasma cell active factor skin care product for removing wrinkles, repairing scars, whitening and firming skin is used for three months, facial skin can be obviously rejuvenated and improved.
The foregoing descriptions of specific exemplary embodiments of the present invention have been presented for purposes of illustration and description. It is not intended to limit the invention to the precise form disclosed, and obviously many modifications and variations are possible in light of the above teaching. The exemplary embodiments were chosen and described in order to explain certain principles of the invention and its practical application to enable one skilled in the art to make and use various exemplary embodiments of the invention and various alternatives and modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims and their equivalents.
Claims (6)
1. An anti-aging skin care product of human autologous plasma cytokine group growth factors is characterized by comprising the following components: 100% of the extract is from autologous blood cell group, and the plasma mixed extract containing complete active cytokines, trace elements, minerals, vitamins and hormones and a plurality of active elements for stimulating cell growth is obtained by extraction, purification, concentration and purification.
2. The method for preparing the anti-aging skin care product of the human autologous plasma cytokine population growth factor according to claim 1, comprising the following steps;
(1) collecting 100mL of human autologous venous blood in a vacuum blood collection tube or a blood collection bag containing an anticoagulant;
(2) transferring the blood collected in the step (1) into 15mL centrifugal tubes (each tube does not exceed 14.5mL), balancing, centrifuging for 300g and 15min respectively, extracting leucocyte layer cells and upper layer plasma, and centrifuging for 700g and 20 min;
(3) mixing the obtained bottom erythrocyte sediment and growth factor protein with plasma in the same tube;
(4) repeatedly freezing and thawing the plasma centrifuge tube containing the growth factor protein obtained in the step (3) to break the cell wall and release the growth factors of the cytokine group;
(5) carrying out high-speed centrifugation on the cells repeatedly frozen and thawed and crushed in the step (4) to remove a small amount of red blood cells, white blood cells and protein fragments to obtain the plasma of the human autologous plasma cytokine population growth factor;
(6) concentrating the plasma containing the human autologous plasma cytokine population growth factor obtained in the step (5) into 12-20mL, evenly packaging into 4.5mL freezing tubes, and storing in an ultra-low temperature refrigerator at-80 ℃ for a long time.
3. The method for preparing the anti-aging skin care product of the human autologous plasma cytokine population growth factor according to claim 2, wherein the collection conditions for collecting 100mL of human autologous venous blood in step (1) are vacuum blood collection tubes or blood collection bags containing anticoagulants.
4. The method for preparing the anti-aging skin care product of the human autologous plasma cytokine population growth factor according to claim 2, wherein the first centrifugation step in the step (2) comprises centrifugation at 300g for 15min, at an increasing speed of 0 and at a decreasing speed of 0; the second step centrifugation condition is 700g, 20min natural centrifugation.
5. The method for preparing the anti-aging skin care product of the human autologous plasma cytokine population growth factor according to claim 2, wherein repeated freezing and thawing are adopted in the step (3) and the step (4), so that the cell factors in the cells after wall breaking are all released under the conditions of quick freezing at-50 to-80 ℃ for 30min and then reviving in water bath at 37 ℃ for 10 min; repeating for 1-2 times.
6. The method for preparing the anti-aging skin care product of the human autologous plasma cytokine population growth factor according to claim 5, wherein the high-speed centrifugation condition is 900g and 10 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010876014.5A CN111773172A (en) | 2020-08-25 | 2020-08-25 | Anti-aging skin care product containing human autologous plasma cytokine group growth factors and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010876014.5A CN111773172A (en) | 2020-08-25 | 2020-08-25 | Anti-aging skin care product containing human autologous plasma cytokine group growth factors and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111773172A true CN111773172A (en) | 2020-10-16 |
Family
ID=72762304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010876014.5A Pending CN111773172A (en) | 2020-08-25 | 2020-08-25 | Anti-aging skin care product containing human autologous plasma cytokine group growth factors and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111773172A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730438A (en) * | 2021-09-03 | 2021-12-03 | 秦红 | Preparation method of conditioned serum and cell filtrate rich in cytokines |
| CN115006711A (en) * | 2022-06-23 | 2022-09-06 | 广东瑞程医学科技有限公司 | Microneedle loaded with active self-regeneration factor and preparation method and application thereof |
-
2020
- 2020-08-25 CN CN202010876014.5A patent/CN111773172A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730438A (en) * | 2021-09-03 | 2021-12-03 | 秦红 | Preparation method of conditioned serum and cell filtrate rich in cytokines |
| CN115006711A (en) * | 2022-06-23 | 2022-09-06 | 广东瑞程医学科技有限公司 | Microneedle loaded with active self-regeneration factor and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102357070B (en) | Hydrolyzed silk protein/ recombinant human Epidermal Growth Factor (rhEGF) compound skin care facial mask and preparation method thereof | |
| CN111773172A (en) | Anti-aging skin care product containing human autologous plasma cytokine group growth factors and preparation method thereof | |
| CN104721129A (en) | Microemulsion biotechnology skin care product | |
| CN110339147A (en) | A kind of composition for external application and application thereof | |
| CN112941010A (en) | Plant callus efficacy filtrate and exosome extraction method | |
| CN111956670A (en) | Preparation method of mesenchymal stem cells and active factor compound freeze-dried product thereof | |
| CN111690600A (en) | Engineered human umbilical cord mesenchymal stem cell exosome, transdermal preparation and application | |
| CN103006511B (en) | Hirudin skin-whitening moisture-keeping conditioning cream and production process thereof | |
| CN110638833A (en) | Composition for promoting hair growth and method of use thereof | |
| CN111202749A (en) | Preparation method of stem cell active factor composition with muscle cell repair function | |
| CN109771322A (en) | Human stem cell factor skin repair composition and its application in skin care item | |
| CN113041206A (en) | Essence containing mesenchymal stem cell factor and preparation method thereof | |
| CN107411998B (en) | Antioxidant mask containing active peptide of hairtail | |
| CN114344454A (en) | Preparation method of autologous fat collagen injection | |
| CN110590932A (en) | Preparation method of umbilical cord mesenchymal stem cell factor freeze-dried powder | |
| CN114288221A (en) | A method for preparing essence containing polypeptide and plant extractive solution with hair growth promoting effect and its application | |
| CN112043619B (en) | Peptide composition with repairing effect and preparation method and application thereof | |
| CN110604714A (en) | Whitening, freckle-removing and anti-aging formula composition and preparation method thereof | |
| CN116831983B (en) | Concentrated growth factor composite gel preparation, preparation method and hair growth application | |
| KR20100096447A (en) | Cosmetic composition comprising matrials cultured adult stem cells derived from swine placenta tissue and proteins extracted therefrom | |
| CN103006512A (en) | Hirudin anti-winkle face-softening conditioning cream and production process thereof | |
| CN109125181B (en) | Antioxidant moisturizing composition and application thereof in anti-aging moisturizing essence | |
| CN111568851A (en) | Method for producing active factors by using perinatal MSC and cosmetic preparation | |
| CN115025035A (en) | Freeze-dried powder, preparation method and mask | |
| CN110840818A (en) | A skin caring and antiaging preparation and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201016 |
|
| RJ01 | Rejection of invention patent application after publication |